Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies. Its technology platforms comprise Pulmonary Technology, which includes technologies for drug formulation, powder processing, powder filling, and packaging, as well as dry powder inhaler devices; and PEGylation Technology designed to increase the performance of various drug classes, including macromolecules, small molecules, and other drugs. The company’s technologies are used in 9 approved products; 2 partner programs that have been filed for with the FDA; and 12 development programs in human clinical trials. Its partnered products include Exubera Inhalation Powder for adult type 1 and type 2 diabetes; Tobramycin inhalation powder, a Phase III clinical product for treating lung infections; Pulmonary dronabinol, a Phase II product for migraine; Ciprofloxacin Inhalation Powder, which is in Phase I clinical trial for lung infections in cystic fibrosis patients; and Pulmonary ostabolin-C, a Phase I product for the treatment of osteoporosis. Its partnered product portfolio comprises Neulasta for neutropenia; PEGASY for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; Cimzia for Crohn’s disease; MIRCERA for renal anemia; Cimzia, a Phase III product for rheumatoid arthritis; Macugen, which is in Phase II clinical trial for diabetic macular edema and retinal vein occlusion; Hematide, a Phase II product for Anemia; and CDP 791, a Phase II product for nonsmall cell lung cancer. In addition, the company develops inhaled antibiotics for adjunctive treatment of pneumonia in ventilated patients; and Amphotericin B inhalation powder for the prevention of pulmonary aspergillosis. The company was founded in 1990 as Inhale Therapeutic Systems, Inc. and changed its name to Nektar Therapeutics in 2003. Nektar Therapeutics is headquartered in San Carlos, California.